Senores PharmaceuticalsNSE:SENORES +3.40%18 Gross Margin % is 62.20% as of Mar. 2026, which is 14% above its 10-year median of 54.63. GuruFocus rates NSE:SENORES with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 937 Drug Manufacturers companies, Senores Pharmaceuticals ranks better than 68.2% on this metric.
NSE:SENORES's Gross Margin % is ranked better than 68.2% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs NSE:SENORES: 59.65
Senores Pharmaceuticals had a gross margin of 62.20% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Senores Pharmaceuticals was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Senores Pharmaceuticals had a gross margin of 62.20% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Senores Pharmaceuticals Gross Margin % Related Terms
Senores Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SENORES vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senores Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Senores Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Senores Pharmaceuticals (NSE:SENORES) has a Gross Margin % of 62.20% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Senores Pharmaceuticals and its competitors. This is 14% above median its historical median of 54.63. Over the past decade, Senores Pharmaceuticals' Gross Margin % has ranged from 42.89 to 63.86. According to the industry distribution chart, Senores Pharmaceuticals ranks #298 out of 937 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Senores Pharmaceuticals' Gross Margin % too high?
Senores Pharmaceuticals' current Gross Margin % of 62.20% is 14% above median its 10-year median of 54.63. Over the past 10 years, this metric has ranged from a low of 42.89 to a high of 63.86. The Drug Manufacturers industry median Gross Margin % is 48.46. Senores Pharmaceuticals' value of 62.20% is 28.4% above this industry median. Based on the distribution chart, Senores Pharmaceuticals ranks #298 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #298 out of 937 companies for Gross Margin %. This puts Senores Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 48.46. Senores Pharmaceuticals' value of 62.20% is 28.4% above this benchmark. Historically, Senores Pharmaceuticals' own Gross Margin % has ranged from 42.89 to 63.86 over the past decade. While the company's 10-year median is 54.63 vs. the industry median of 48.46, Senores Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senores Pharmaceuticals's current Gross Margin % of 62.20% is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Senores Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current Gross Margin % is 62.20%, which is 14% above median its own 10-year median of 54.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current Gross Margin % of 62.20%. The current Gross Margin % is 62.20%, which is 14% above median its 10-year median of 54.63 and 28.4% above the Drug Manufacturers industry median of 48.46. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current Gross Margin % is 62.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score
Get the complete analysis for NSE:SENORES
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
